Mannose supplementation in PMM2-CDG
Abstract In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper “Dietary mannose supplementation in phosphomannomutase 2 deficiency (...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-021-01988-x |
id |
doaj-f064310920a14019a2b38a80436c504c |
---|---|
record_format |
Article |
spelling |
doaj-f064310920a14019a2b38a80436c504c2021-08-15T11:29:58ZengBMCOrphanet Journal of Rare Diseases1750-11722021-08-011611310.1186/s13023-021-01988-xMannose supplementation in PMM2-CDGRoman Taday0Julien H. Park1Marianne Grüneberg2Ingrid DuChesne3Janine Reunert4Thorsten Marquardt5Department of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterDepartment of General Pediatrics, University Children’s Hospital MünsterAbstract In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper “Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)” has shown that further investigation of mannose in PMM2-CDG is worthwhile alongside other treatment options and should not be dismissed off-hand without the willingness to prove or disprove it in controlled prospective clinical trials.https://doi.org/10.1186/s13023-021-01988-xPMM2Congenital disorder of glycosylationMannoseGalactoseTherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roman Taday Julien H. Park Marianne Grüneberg Ingrid DuChesne Janine Reunert Thorsten Marquardt |
spellingShingle |
Roman Taday Julien H. Park Marianne Grüneberg Ingrid DuChesne Janine Reunert Thorsten Marquardt Mannose supplementation in PMM2-CDG Orphanet Journal of Rare Diseases PMM2 Congenital disorder of glycosylation Mannose Galactose Therapy |
author_facet |
Roman Taday Julien H. Park Marianne Grüneberg Ingrid DuChesne Janine Reunert Thorsten Marquardt |
author_sort |
Roman Taday |
title |
Mannose supplementation in PMM2-CDG |
title_short |
Mannose supplementation in PMM2-CDG |
title_full |
Mannose supplementation in PMM2-CDG |
title_fullStr |
Mannose supplementation in PMM2-CDG |
title_full_unstemmed |
Mannose supplementation in PMM2-CDG |
title_sort |
mannose supplementation in pmm2-cdg |
publisher |
BMC |
series |
Orphanet Journal of Rare Diseases |
issn |
1750-1172 |
publishDate |
2021-08-01 |
description |
Abstract In this response to the letter by Witters et al., we refer to the authors' arguments regarding spontaneous enhancement of glycosylation and the claim, that mannose has no place in the treatment of PMM2-CDG. Our paper “Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)” has shown that further investigation of mannose in PMM2-CDG is worthwhile alongside other treatment options and should not be dismissed off-hand without the willingness to prove or disprove it in controlled prospective clinical trials. |
topic |
PMM2 Congenital disorder of glycosylation Mannose Galactose Therapy |
url |
https://doi.org/10.1186/s13023-021-01988-x |
work_keys_str_mv |
AT romantaday mannosesupplementationinpmm2cdg AT julienhpark mannosesupplementationinpmm2cdg AT mariannegruneberg mannosesupplementationinpmm2cdg AT ingridduchesne mannosesupplementationinpmm2cdg AT janinereunert mannosesupplementationinpmm2cdg AT thorstenmarquardt mannosesupplementationinpmm2cdg |
_version_ |
1721206806732079104 |